

Special Issue

Novel Insight in the Etiology of CRC: Genetics, Diagnosis, Management and Risk Assessment

Message from the Guest Editors

Early onset CRC (EOCRC) is reported to have increasing incidence, and as many as ~18% of patients diagnosed with CRC < age of 50 years (EOCRC) have pathogenic germline variants in genes that are not traditionally associated with CRC, including ATM, CHEK2, BRCA1, BRCA2, CDKN2A and PALB2 genes. The causes for familial clustering of CRC in older ages are less clear. An increase in CRC incidence should be caused by environmental factors, including interaction between genetic and environmental causative factors.

Comprehensive testing for multiple genes, both in families and in incident cases, is now generating new knowledge for these topics. Early detection of and screening for cancer may cause overdiagnosis. In addition to treatment of cancer, health care includes knowledge and public education on lifestyle, clean environment, and the inherited cancer syndromes' medical genetic services. This should cover both high- and low-income areas. The current issue aims to increase knowledge for such aims.

Guest Editors

Dr. Mev Dominguez Valentin

Department of Tumor Biology, The Norwegian Radium Hospital, Part of Oslo University Hospital, Oslo, Norway

Dr. Pål Møller

Department of Tumor Biology, The Norwegian Radium Hospital, Part of Oslo University Hospital, Oslo, Norway

Deadline for manuscript submissions

closed (20 February 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/86395

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)